Advertisement
Screener

iSpecimen Inc. (ISPC) Overview

iSpecimen Inc. (ISPC) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.98; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -6.66; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.48; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -16.78; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$1.15$2.48$5.37$11.60$25.07$54.182025-09-292026-09-29$1.15$7.86$53.71$367.12$2,509.40$17,152.802021-09-292026-09-29$1.15$7.86$53.71$367.12$2,509.40$17,152.802021-06-172026-09-29$1.15$7.86$53.71$367.12$2,509.40$17,152.802021-06-172026-09-29$1.15$7.86$53.71$367.12$2,509.40$17,152.802021-06-172026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$1.23
Previous close
$1.21
Change
$0.02
Change (%)
1.65%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

ISPC
-88.17%
S&P 500
(m)

1 year

ISPC
-97.42%
S&P 500
(m)

3 years

ISPC
-99.75%
S&P 500
(m)

5 years

ISPC
-99.97%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.98

-28.63-21.55-14.46-7.38-0.3031 Mar 2025: estimate (m); actual -28.5531 Mar 2025(m)30 Jun 2025: estimate (m); actual -16.7830 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.4830 Sept 2025(m)31 Mar 2026: estimate (m); actual -6.6631 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.9830 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.98(m)(m)
1 Jan 202631 Mar 2026(m)-6.66(m)(m)
1 Jul 202530 Sept 2025(m)-0.48(m)(m)
1 Apr 202530 Jun 2025(m)-16.78(m)(m)
1 Jan 202531 Mar 2025(m)-28.55(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -2.28

-24.63-18.72-12.80-6.89-0.9831 Dec 2021: estimate (m); actual -2.0931 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.1631 Dec 2022(m)31 Dec 2023: estimate (m); actual -24.5531 Dec 2023(m)31 Dec 2024: estimate (m); actual -17.5831 Dec 2024(m)31 Dec 2025: estimate (m); actual -2.2831 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-2.28(m)(m)
1 Jan 202431 Dec 2024(m)-17.58(m)(m)
1 Jan 202331 Dec 2023(m)-24.55(m)(m)
1 Jan 202231 Dec 2022(m)-1.16(m)(m)
1 Jan 202131 Dec 2021(m)-2.09(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 0.15M ■ Earnings -1.36M — Profit margin -896.94%

-5.62M-9663.2%-3.49M-6740.8%-1.36M-3818.4%0.77M-895.9%30 Sept 2025: revenue 0.11M; earnings -2.78M; profit margin -2608.68%30 Sept 202531 Dec 2025: revenue 0.05M*; earnings -5.00M*; profit margin -9662.19%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 0.16M; earnings -2.28M; profit margin -1458.39%31 Mar 202630 Jun 2026: revenue 0.15M; earnings -1.36M; profit margin -896.94%30 Jun 2026

31 Dec 2025 ■ Revenue 1.93M ■ Earnings -10.49M — Profit margin -543.68%

-15.25M-544.7%-5.78M-395.6%3.68M-246.6%13.15M-97.5%31 Dec 2022: revenue 10.40M; earnings -10.25M; profit margin -98.50%31 Dec 202231 Dec 2023: revenue 9.93M; earnings -11.10M; profit margin -111.80%31 Dec 202331 Dec 2024: revenue 9.29M; earnings -12.50M; profit margin -134.51%31 Dec 202431 Dec 2025: revenue 1.93M; earnings -10.49M; profit margin -543.68%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$1.23(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$1.23High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning ISPC

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-11.42M
Profit margin
-2449.04%
Return on assets · 12 month
-170.10%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.47M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-1.60%*
Total return · month
-20.13%*
Total return · quarter
-55.91%*
Total return · half year
-78.94%*
Total return · year to date
-88.17%*
Total return · 1 year
-97.42%*
Total return · 3 years
-99.75%*
Total return · 5 years
-99.97%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$466.30K
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

iSpecimen Inc. Overview

View more →

(m)

(m)

SEC CIK
1558569
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
8 CABOT ROAD, SUITE 1800, WOBURN, Massachusetts, 08101, United States
Fiscal year end
1231
Phone
781-301-6700

Similar stocks

Stock NameCountryMarket CapPE Ratio
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
OneMedNet Corp (ONMD)$0.042B
bioAffinity Technologies, Inc. (BIAF)United States$0.063B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14